A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

This study has been completed.
Ambit Biosciences Corporation
Information provided by (Responsible Party):
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
First received: July 7, 2011
Last updated: October 29, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)